In Vitro Diagnostics Market (Technology Type: Point-of-care, Molecular Diagnostics, Immunoassays, Clinical Chemistry, Whole Blood Glucose Monitoring, Hematology, Clinical Microbiology, Coagulation & Hemostasis, and Others; Application: Drug Testing, Infectious Diseases, Oncology, Metabolic Diseases, Autoimmune Diseases, and Others; and End-user: Diagnostic Laboratories, Hospitals, Academic & Research Centers, Home Care, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030
The global In Vitro Diagnostics market gathered revenue around USD 75.2 billion in 2021 and market is set to grow USD 120.9 billion by the end of 2030 and is estimated to expand at a modest CAGR of 9.3% during the prediction period 2022 to 2030.
In vitro diagnostics are tests done on samples such as blood or tissue that have been taken from the human body. Diagnosis of infectious diseases is one of the leading applications of in vitro diagnostics. Investment in the development of new diagnostics tools for diagnosing various infectious diseases has been increasing. In April 2017, the U.S. Department of Health and Human Services awarded a contract to Siemens Healthineers to develop Zika virus immunoassay test to use on its Advia platform of immunoassay analyzers. The prevalence of hepatitis and HIV diseases is increasing globally and is expected to drive the demand for in vitro diagnostic testing. According to the World Health Organization (WHO), in July 2021, an estimated 58 .2 million people across the world had hepatitis C infection. WHO also stated that around 38.7 million people were affected with HIV across the world in 2021.
The rise in prevalence of these infectious diseases is likely to increase the demand for diagnostic tests, which in turn is projected to propel the global in vitro diagnostics market.
New innovative technologies such as RT-PCR and next generation sequencing provide a comparatively less expensive way of diagnosis, prognosis, and therapy selection in patients throughout their treatment plan. This helps physicians frame appropriate therapeutic regimes for patients suffering from diseases.
In addition, surge in demand for point-of-care services is likely to drive the in vitro diagnostics market. Point-of-care provides quick and accurate results compared to traditional methods.
Report Scope of the In Vitro Diagnostics Market
US$ 120.9 Billion by 2030
CAGR of 9.3% from 2022 to 2030
Fastest Growing Market
2022 to 2030
Technology Type, Application, End-user and Region,
F. Hoffmann-La Roche Ltd., Danaher, Siemens Healthineers, bioMérieux SA, Abbott, Diasorin, Meridian Bioscience, Inc., Ortho-Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., and Sysmex Corporation.
Clinical Chemistry Segment to Dominate Global In Vitro Diagnostics Market
In terms of technology type, the global in vitro diagnostics market has been classified into point-of-care, molecular diagnostics, immunoassays, clinical chemistry, whole blood glucose monitoring, hematology, clinical microbiology, coagulation & hemostasis, and others. The clinical chemistry segment dominated the global market in terms of share in 2021. Increase in the geriatric population and rise in awareness are expected to propel the segment during the forecast period.
Ongoing Prevalence of COVID-19 Fueling Demand for In-vitro Diagnostic Tests
The rising incidence of infectious diseases is playing an important role in growth of the in vitro diagnostics market. The outbreak of the COVID-19 pandemic has led to investments in new research lines for diagnostics and treatment of infectious diseases. The medical industry has tasted some success in developing resilient diagnostic technologies for COVID-19. However, there is a long way ahead for the medical and healthcare sectors.
As new research lines emerge for the management of the pandemic, the global in-vitro diagnostics market would grow at a steady pace. Furthermore, there has been an increase in the number of cases for COVID-19 and its variants. This factor has also played an underhanded role in driving demand for in vitro diagnostic tests. The analysis of blood samples has gained relevance across several verticals of the healthcare sector.
Ever-changing Oncology Landscape Challenging Healthcare Sector
Companies in the in vitro diagnostics market are increasing R&D in testing of infectious diseases, drug testing, oncology, autoimmune diseases, and metabolic diseases, among others. The unprecedented demand for improved diagnostics in the field of oncology is anticipated to drive the demand within the market. In addition, the discovery of new forms of tumors in the human body has raised concerns across the healthcare sector.
Besides, the rising occurrence of known tumors among the masses has transcended as a challenge for the healthcare sector. Therefore, the quest of the healthcare industry to resolve the growing incidence of various types of cancers is projected to fuel the growth of the global in vitro diagnostics market. Furthermore, the collection of samples for biopsies and other similar tests has also supported market maturity. The next few years would be crucial in understanding the direction of growth for the in vitro diagnostics market. The revolutionary growth of the diagnostics domain could prove to be a game changer for market vendors.
North America to Lead Global In Vitro Diagnostics Market
In terms of region, the global in vitro diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The U.S. dominated the market in North America in 2021 due to adoption of new technologies such as next generation sequencing, higher awareness, significant health care spending in overall national budgets, early availability of advanced technologies, and higher penetration of research activities across the country.
Some of the prominent players in the In Vitro Diagnostics Market include:
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers
- bioMérieux SA
- Meridian Bioscience, Inc.
- Ortho-Clinical Diagnostics, Inc.
- Thermo Fisher Scientific, Inc.
- Sysmex Corporation
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global In Vitro Diagnostics Market: Segmentation
In Vitro Diagnostics Market, by Technology Type
- Molecular Diagnostics
- Clinical Chemistry
- Whole Blood Glucose Monitoring
- Clinical Microbiology
- Coagulation and Hemostasis
In Vitro Diagnostics Market, by Application
- Drug Testing
- Infectious Diseases
- Metabolic Diseases
- Autoimmune Diseases
In Vitro Diagnostics Market, by End-user
- Diagnostic Laboratories
- Academic & Research Centers
- Home Care
- United Kingdom
- Rest of Europe
- Southeast Asia
- Rest of Asia Pacific
- Rest of Latin America
Middle East & Africa (MEA)
- North Africa
- South Africa
- Rest of Middle East & Africa
Key Points Covered in In Vitro Diagnostics Market Study:
- Growth of In Vitro Diagnostics in 2022
- Market Estimates and Forecasts (2017-2030)
- Brand Share and Market Share Analysis
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Recommendation on Key Winning Strategies
- COVID-19 Impact on Demand for In Vitro Diagnostics and How to Navigate
- Key Product Innovations and Regulatory Climate
- In Vitro Diagnostics Consumption Analysis
- In Vitro Diagnostics Production Analysis
- In Vitro Diagnostics and Management